CENTEK(SZ:000931)2022-10-27 16:00Financial Performance - The company's operating revenue for Q3 2022 was CNY 524,657,605.30, representing a 3.02% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 9,393,163.75, a significant increase of 114.41% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was CNY 0.0125, reflecting a 114.41% increase year-over-year[5] - Total operating revenue for the current period reached ¥1,538,628,824.11, an increase of 5.3% compared to ¥1,460,919,478.78 in the previous period[53] - Net profit for the current period was ¥28,110,703.15, a significant recovery from a net loss of ¥32,739,792.19 in the previous period[54] - The company reported a basic and diluted earnings per share of ¥0.0175, compared to a loss per share of ¥0.0663 in the previous period[55] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,656,113,459.21, a decrease of 1.11% from the end of the previous year[5] - The company's current assets totaled CNY 1,593,821,119.33, showing a slight increase from CNY 1,582,962,234.60 at the beginning of the year[48] - The total liabilities decreased to CNY 1,814,524,799.17 from CNY 1,883,729,548.00[50] - The company's cash and cash equivalents were CNY 148,119,672.15, down from CNY 170,199,518.79 at the beginning of the year[48] - Short-term borrowings rose to CNY 490,000,000.00 from CNY 453,152,290.00, reflecting an increase of about 8.1%[50] - The company's long-term borrowings increased significantly to CNY 193,500,000.00 from CNY 57,500,000.00, marking an increase of approximately 236.5%[50] Research and Development - Research and development expenses for the period amounted to CNY 80,754,900, marking an 82.05% increase compared to the previous year[10] - Research and development expenses increased to ¥80,754,864.50 from ¥44,358,033.15, indicating a focus on innovation[53] Shareholder Information - The total number of common shareholders at the end of the reporting period is 76,643[15] - The largest shareholder, Gome Holdings Group, holds 27.78% of shares, totaling 209,213,228 shares, with 124,101,400 shares pledged[15] - Gome Electrical Appliances Company, the second-largest shareholder, holds 7.37% of shares, totaling 55,500,355 shares, with 50,000,000 shares pledged[15] - Gome Holdings has pledged a total of 111,601,400 shares, accounting for 53.34% of its holdings and 14.81% of the company's total share capital[21] Tax and Refunds - The company received tax refunds amounting to CNY 20,385,200, a substantial increase of 1,187.25% year-over-year, due to VAT refund policies[12] - The company reported a significant decrease in tax expenses, down to ¥24,615,358.29 from ¥47,683,071.97 in the previous period[53] Corporate Governance - The company has completed the election of the eighth board of directors and the eighth supervisory board, with key appointments including Xu Zhongmin as chairman and Hou Zhanjun as president[17] - The independent director's allowance has been adjusted from 90,000 RMB to 120,000 RMB per year to enhance their decision-making support and supervision[18] - The company has increased its information disclosure media to include Shanghai Securities Journal, enhancing communication with the market[19] Strategic Partnerships - The company signed a cooperation framework agreement with Beijing Youxun Medical Laboratory to leverage resources in the healthcare sector[22] - The strategic cooperation agreement between the parties aims to leverage Party A's operational advantages and Party B's expertise in COVID-19 testing, with revenue sharing based on the new nucleic acid testing services[23] Legal and Compliance - The third quarter report has not been audited[58] - The announcement was made by the Board of Directors on October 27, 2022[59]